The Pfizer story

What drives the business

• Pfizer depends on replenishing a concentrated drug portfolio: 12 products each generated more than $1 billion in revenue and collectively accounted for 65% of total revenue in 2025, with Eliquis alone contributing 13%.
• The acquisitions of Seagen and Metsera represent significant investments in oncology and obesity as revenue from Comirnaty and Paxlovid has fallen substantially.
• The Innovent Biologics agreement, completed in July 2026, covers 12 early-stage cancer medicines and includes a $650 million upfront payment, up to $9.85 billion in milestone payments, royalties and profit sharing on selected programs.
• In the quarter to June 2026, operational revenue growth of 19% for Eliquis, 23% for Padcev, 8% for the Vyndaqel family and 37% for Lorbrena helped revenue excluding Comirnaty and Paxlovid grow 5% operationally.
• Cost reductions are another part of the transition, with Pfizer expecting approximately $6.7 billion in net savings from cost realignment and $3.0 billion from manufacturing optimization through 2029.

What the price assumes

At $28.72, the reverse DCF implies that free cash flow after stock pay grows 4.5% a year for ten years using a 10.2% discount rate.

That compares with -6.9% a year over the last 10 years and the TenQ check's bar of -1.4%, which moves the historical rate halfway toward 4%.

Pfizer generated $11.0 billion in free cash flow over the last twelve months, with $947 million in stock-based pay, but its 6.7% free cash flow yield is below its historical 9.2%.

Value PFE on your own assumptions

What could change the story

• Pfizer anticipates significant revenue reductions from patent and regulatory exclusivity expirations from 2026 through 2030, putting pressure on newer products to replace established revenue.
• The sigvotatug vedotin trial did not show a statistically significant improvement in overall survival in its overall population, illustrating the development risk behind Pfizer's oncology investment and related impairment.
• U.S. drug pricing initiatives, including TrumpRx.gov discounts and Medicare pricing changes, could reduce revenue, while the tariff agreement with the Trump Administration depends on further U.S. manufacturing investment.
• Paxlovid revenue fell 95% operationally and Comirnaty revenue fell 34% operationally in the quarter to June 2026, reflecting lower infections, government purchases and vaccine utilization, among other factors.
• Total debt of $63.2 billion against $8.3 billion in cash and short-term investments limits financial flexibility, and Pfizer fails TenQ's checks on near-term liquidity, debt trends and debt repayment capacity.

What to watch next

• The next releases will test Pfizer's raised 2026 revenue guidance of $60.5 billion to $62.5 billion, including approximately $4 billion from Covid products, against continued growth in its non-Covid portfolio.
• Pfizer reaffirmed 2026 adjusted diluted EPS guidance of $2.80 to $3.00 despite an expected approximately $0.10 unfavorable impact from the Innovent transaction, making operating costs and product mix important measures of progress.
• Cash flow and debt reduction will show how Pfizer balances pipeline spending and dividends, following $5.3 billion in internal research and development investment and $4.9 billion in cash dividends during the first six months of 2026.
• Progress toward approximately $5.7 billion in cost realignment savings by the end of 2026 will provide an earlier test of execution than the expanded savings programs running through 2029.

Sources

• Pfizer's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The PFE stock report, for every figure and check